JCR Pharmaceuticals Co., Ltd.
4552.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥13 | ¥9 | ¥7 | ¥9 |
| % Growth | 49.3% | 19.1% | -22% | – |
| Cost of Goods Sold | ¥2 | ¥2 | ¥4 | ¥3 |
| Gross Profit | ¥11 | ¥6 | ¥3 | ¥7 |
| % Margin | 84.3% | 72.1% | 39.2% | 71% |
| R&D Expenses | ¥4 | ¥3 | ¥6 | ¥3 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥3 | ¥3 | ¥3 | ¥3 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥8 | ¥7 | ¥9 | ¥7 |
| Operating Income | ¥3 | -¥1 | -¥6 | -¥0 |
| % Margin | 23% | -7.5% | -82.6% | -0.7% |
| Other Income/Exp. Net | ¥0 | -¥0 | -¥0 | ¥0 |
| Pre-Tax Income | ¥3 | -¥1 | -¥6 | ¥0 |
| Tax Expense | ¥1 | -¥0 | -¥2 | ¥0 |
| Net Income | ¥2 | -¥1 | -¥4 | ¥0 |
| % Margin | 17.6% | -6.4% | -58.2% | 1.2% |
| EPS | 18.51 | -4.48 | -33.8 | 0.93 |
| % Growth | 513.2% | 86.7% | -3,734.4% | – |
| EPS Diluted | 18.5 | -4.48 | -33.8 | 0.94 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥0 | ¥0 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥1 | ¥1 | ¥1 | ¥1 |
| EBITDA | ¥4 | ¥0 | -¥5 | ¥1 |
| % Margin | 32% | 0.8% | -72% | 8% |